<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963556</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01079</org_study_id>
    <nct_id>NCT04963556</nct_id>
  </id_info>
  <brief_title>Effects of Red Bull® on the Effects of Training and Haemodynamic Parameters</brief_title>
  <official_title>Effects of Red Bull® on the Effects of Moderate Endurance Training Measured by Haemodynamic Parameters</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Basel</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The consumption of Energy Drinks (EDs) can acutely lead to negative side effects, such as&#xD;
      raised blood pressure and impaired endothelial function. Nevertheless, they are sold&#xD;
      worldwide and are often consumed before physical activity (PA). In contrast to the blood&#xD;
      pressure elevating effect of EDs, PA leads to a reduction of blood pressure. The effect of ED&#xD;
      consumption on blood pressure response during and after endurance training is currently&#xD;
      unresolved.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      A total of 23 participants (eleven men, twelve women) were evaluated in the intervention&#xD;
      study with a blinded Cross-Over Design. They consumed on two different days either 355 ml Red&#xD;
      Bull (RB) or 355 ml Placebo (Pla) in randomised order. The peripheral (PBP) and central blood&#xD;
      pressure (CBP) were measured before, during and after a 30-minute aerobic endurance training,&#xD;
      by the Schiller BR-102 plus PWA device.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      The consumption of Energy Drinks (EDs) can acutely lead to negative side effects, such as&#xD;
      raised blood pressure and impaired endothelial function. Nevertheless, they are sold&#xD;
      worldwide and are often consumed before physical activity (PA). In contrast to the blood&#xD;
      pressure elevating effect of EDs, PA leads to a reduction of blood pressure. The effect of ED&#xD;
      consumption on blood pressure response during and after endurance training is currently&#xD;
      unresolved.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      A total of 23 participants (eleven men, twelve women) were evaluated in the intervention&#xD;
      study with a blinded Cross-Over Design. They consumed on two different days either 355 ml Red&#xD;
      Bull (RB) or 355 ml Placebo (Pla) in randomised order. The peripheral (PBP) and central blood&#xD;
      pressure (CBP) were measured before, during and after a 30-minute aerobic endurance training,&#xD;
      by the Schiller BR-102 plus PWA device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2017</start_date>
  <completion_date type="Actual">April 15, 2018</completion_date>
  <primary_completion_date type="Actual">November 1, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Blinded to verum or placebo drink</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on blood pressure</measure>
    <time_frame>24 hours</time_frame>
    <description>Effect on systolic and diastolic blood pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>24 hours</time_frame>
    <description>central pulse wave velocity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Effects of; Food, Allergic</condition>
  <arm_group>
    <arm_group_label>Red Bull</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drinking of 355 ml Red Bull</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drinking of 355 ml sweetened water</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Red Bull</intervention_name>
    <description>Drinking of Red Bull before exercise</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Red Bull</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  No known cardiovascular diseases such as arterial hypertension and diabetes mellitus.&#xD;
&#xD;
          -  No ophthalmological diseases such as glaucoma or macular degeneration.&#xD;
&#xD;
          -  No regular medication&#xD;
&#xD;
          -  No vasodilator abuse for 24 h before the respective intervention (e.g. smoking, use of&#xD;
             stimulants, β-blockers).&#xD;
&#xD;
          -  No pregnancy (anamnestic)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arno Schmidt-Trucksäss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Basel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>4052</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 5, 2021</last_update_submitted>
  <last_update_submitted_qc>July 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Basel</investigator_affiliation>
    <investigator_full_name>Arno Schmidt-Trucksäss</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

